PR Newswire
NEWARK, Calif., Nov. 13, 2023
61.7% of patients on seladelpar 10 mg achieved the primary composite endpoint vs. 20.0% of patients on placebo (p<0.0001)
Seladelpar achieved a highly significant rate of alkaline phosphatase normalization and reductions in patient-reported pruritus vs. placebo
The results will support the submission of global market authorization applications
NEWARK, Calif., Nov. 13, 2023 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar, or PPARCopyright CNW Group 2023
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member